Get started
Work

Supplementary Material 1 from Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors

Year: 2024
Type: supplementary-materials
Abstract: Supplementary Table S1, Supplementary Table S2, Supplementary Figure S1
DOI: 10.1158/1078-0432.25728644.v1
Authors: Ryan B. Corcoran, Khanh T. Do, Jeong E. Kim, James M. Cleary, Aparna R. Parikh, Oladapo O. Yeku, Niya Xiong, Colin D. Weekes, Jennifer Veneris, Leanne G. Ahronian, Gianluca Mauri, Jun Tian, Bryanna L. Norden, Alexa G. Michel, Emily E. Van Seventer, Giulia Siravegna, Kyle Camphausen, Gary Chi, Isobel J. Fetter, Joan S. Brugge, Helen Chen, Naoko Takebe, Richard T. Penson, Dejan Juric, Keith T. Flaherty, Ryan J. Sullivan, Jeffrey W. Clark, Rebecca S. Heist, Ursula A. Matulonis, Joyce F. Liu, Geoffrey I. Shapiro
Institutions: Harvard University, Massachusetts General Hospital, Dana-Farber Cancer Institute, Asan Medical Center, University of Ulsan, University of Milan, Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, National Cancer Institute
Language: English
Open Access status: gold
OpenAlex ID: W4396543330
Cites:
Cited by:
Related to: 10